Locoregional treatment for hepatocellular carcinoma:The best is yet to come

作     者：Naveen Kalra Pankaj Gupta Yogesh Chawla Niranjan Khandelwal 

作者机构：Deparment of Radiodiagnosis and ImagingPGIMER Deparment of HepatologyPGIMER 

出 版 物：《World Journal of Radiology》 (世界放射学杂志（英文版）（电子版）)

年 卷 期：2015年第7卷第10期

页      面：306-318页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 1009[医学-特种医学] 10[医学] 

主　　题：Hepatocellular carcinoma High intensity focussed u 

摘      要：Hepatocellular carcinoma(HCC) is the sixth-most common type of cancer worldwide. The only definitive treatment modalities capable of achieving a cure are hepatic resection and hepatic transplantation. However, most patients are not candidates for these therapies. Overall, treatment options are driven by the stage of HCC. Early-stage disease is treated with ablative therapies, with radiofrequency ablation the ablative therapy of choice. Microwave ablation and irreversible electroporation are the other upcoming alternatives. Intermediate-stage disease is managed with transarterial chemoembolization(TACE), while advanced-stage disease is managed by sorafenib, with TACE and radioembolization as other alternatives.